At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial of Probiotics in Preventing Complication Related to Portal Hypertension in Cirrhotic Patients
In Brief
A clinical study evaluating GK#10 and Placebo for Liver Cirrhosis and Portal Hypertension. Completed, enrolled 49 participants across 1 site.
Detailed Summary
Recent studies indicate that probiotics can stimulate intestinal immunity and tighten the junctions of epithelial cells. By these ways, probiotics can reduce bacterial translocation; hence, they can ameliorate systemic inflammatory status. Because cirrhotic patients with portal hypertension often suffer from infections from intestinal flora, the investigators speculate that probiotics will be beneficial to those patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Portal Hypertension
CountriesTaiwan
CollaboratorsGrape King Bio Ltd.
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedMay 2012
Primary CompletionAug 2013
TodayJul 2026
First PostedMay 15, 2012
Enrollment StartApr 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.1 years ago
Interventions
GK#10dietary
GK#10, 1 pack tid
Placebodrug
Placebo 1 pack tid po